IMU Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$1,544,840.00
Insider Selling (Last 12 Months): A$630,000.00

Imugene Insider Trading History Chart

This chart shows the insider buying and selling history at Imugene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Imugene Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for IMU up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Imugene Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2022Jakob DupontInsiderIssued2,100,000A$0.18A$367,500.00
11/4/2022Charles WalkerInsiderBuy25,000,000A$0.04A$1,075,000.00
6/9/2022Charles WalkerInsiderBuy128,000A$0.16A$19,840.00
6/7/2022Lesley RussellInsiderBuy10,000,000A$0.05A$450,000.00
2/7/2022Jens EcksteinInsiderSell2,100,000A$0.30A$630,000.00
12/13/2021Paul HopperInsiderSell1,248,900A$0.49A$611,961.00
10/22/2021Paul HopperInsiderIssued1,248,600A$0.02A$18,729.00
7/1/2021Lesley RussellInsiderBuy15,000,000A$0.04A$630,000.00
5/28/2021Leslie (Mi Ok) ChongInsiderExercise13,844,444A$0.05A$622,999.98
5/25/2021Leslie (Mi Ok) ChongInsiderSell4,485,889A$0.37A$1,646,321.26
5/21/2021Charles WalkerInsiderSell3,500,000A$0.35A$1,235,500.00
12/22/2020Leslie ChongInsiderExercise98,765A$0.04A$3,950.60
12/16/2020Axel HoosInsiderExercise15,000,000A$0.04A$615,000.00
8/10/2020Charles WalkerInsiderSell4,500,000A$0.06A$261,000.00
8/4/2020Leslie ChongInsiderBuy27,000,000A$0.02A$405,000.00
3/23/2020Charles WalkerInsiderBuy172,500A$0.02A$2,760.00
3/16/2020Leslie ChongInsiderBuy475,240A$0.02A$8,554.32
3/12/2020Leslie ChongInsiderBuy400,000A$0.02A$8,800.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Imugene (ASX:IMU)

Imugene logo
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Read More on Imugene

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


12,699,963 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Imugene?

Imugene's top insider investors include:
  1. Charles Walker (Insider)
  2. Charles Walker (Insider)
  3. Jakob Dupont (Insider)
  4. Jens Eckstein (Insider)
  5. Lesley Russell (Insider)
  6. Leslie (Mi Ok) Chong (Insider)
  7. Paul Hopper (Insider)
Learn More about top insider investors at Imugene.